Ann-Katrine Jakobsen

Ann-Katrine Jakobsen

Auto-generated profile, based on publicly available information

Ann-Katrine Jakobsen

Department of Pathology, Aarhus University Hospital, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
CTCinzia Tesauro
Cinzia Tesauro
ASAnne Katrine Simonsen
Anne Katrine Simonsen
MAMarie Bech Andersen
Marie Bech Andersen
KPKamilla Wandsoe Petersen
Kamilla Wandsoe Petersen
EKEmil Laust Kristoffersen
Emil Laust Kristoffersen
IGIrina Gromova
Irina Gromova
Background: Camptothecin (CPT) and its derivatives are currently used as second- or third-line treatment for patients with endocrine-resistant breast cancer (BC). These drugs convert nuclear enzyme DNA topoisomerase I (TOP1) to a cell poison with the potential to damage DNA by increasing the half-life of TOP1-DNA cleavage complexes (TOP1cc), ultimately resulting in cell death. In small and non-randomized trials for BC, researchers have observed extensive variation in CPT response rates, ranging from 14 to 64%. This variability may be due to the absence of reliable selective parameters for patient stratification. BC cell lines may serve as feasible models for generation of functional criteria that may be used to predict drug sensitivity for patient stratification and, thus, lead to more appropriate applications of CPT in clinical trials. However, no study published to date has included a comparison of multiple relevant parameters and CPT response across cell lines corresponding to specific BC subtypes.Method: We evaluated the levels and possible associations of seven parameters including the status of theTOP1gene (i.e. amplification), TOP1 protein expression level, TOP1 activity and CPT susceptibility, activity of the tyrosyl-DNA phosphodiesterase 1 (TDP1), the cellular CPT response and the cellular growth rate across a representative panel of BC cell lines, which exemplifies three major BC subtypes: Luminal, HER2 and TNBC.Results: In all BC cell lines analyzed (without regard to subtype classification), we observed a significant overall correlation between growth rate and CPT response. In cell lines derived from Luminal and HER2 subtypes, we observed a correlation betweenTOP1gene copy number, TOP1 activity, and CPT response, although the data were too limited for statistical analyses. In cell lines representing Luminal and TNBC subtypes, we observed a direct correlation between TOP1 protein abundancy and levels of enzymatic activity. In all three subtypes (Luminal, HER2, and TNBC), TOP1 exhibits approximately the same susceptibility to CPT. Of the three subtypes examined, the TNBC-like cell lines exhibited the highest CPT sensitivity and were characterized by the fastest growth rate. This indicates that breast tumors belonging to the TNBC subtype, may benefit from treatment with CPT derivatives.Conclusion: TOP1 activity is not a marker for CPT sensitivity in breast cancer.

1 August 2015 in Experimental and Molecular Pathology
Verified
Journal Article
Closed access
AJAnn-Katrine Jakobsen
Ann-Katrine Jakobsen
KLKristina Lystlund Lauridsen
Kristina Lystlund Lauridsen
ESEvelyn Benuja Samuel
Evelyn Benuja Samuel
JPJoanna Proszek
Joanna Proszek
BKBirgitta Knudsen
Birgitta Knudsen
MSMagnus Stougaard
Magnus Stougaard

10 January 2014 in Sensors
Verified
Journal Article
Open access
PDF file
JPJoanna Proszek
Joanna Proszek
ARAmit Roy
Amit Roy
AJAnn-Katrine Jakobsen
Ann-Katrine Jakobsen
RFRikke Frøhlich
Rikke Frøhlich
BKBirgitta Knudsen
Birgitta Knudsen
MSMagnus Stougaard
Magnus Stougaard
Human topoisomerase I (hTopI) is an essential cellular enzyme. The enzyme is often upregulated in cancer cells, and it is a target for chemotherapeutic drugs of the camptothecin (CPT) family. Response to CPT-based treatment is dependent on hTopI activity, and reduction in activity, and mutations in hTopI have been reported to result in CPT resistance. Therefore, hTOPI gene copy number, mRNA level, protein amount, and enzyme activity have been studied to explain differences in cellular response to CPT. We show that Rolling Circle Enhanced Enzyme Activity Detection (REEAD), allowing measurement of hTopI cleavage-religation activity at the single molecule level, may be used to detect posttranslational enzymatic differences influencing CPT response. These differences cannot be detected by analysis of hTopI gene copy number, mRNA amount, or protein amount, and only become apparent upon measuring the activity of hTopI in the presence of CPT. Furthermore, we detected differences in the activity of the repair enzyme tyrosyl-DNA phosphodiesterase 1, which is involved in repair of hTopI-induced DNA damage. Since increased TDP1 activity can reduce cellular CPT sensitivity we suggest that a combined measurement of TDP1 activity and hTopI activity in presence of CPT will be the best determinant for CPT response.

10 March 2018 in Cancer Genomics & Proteomics
Verified
Journal Article
Open access
PDF file
EKEigil Kjeldsen
Eigil Kjeldsen
CNChristine J.F. Nielsen
Christine J.F. Nielsen
ARAmit Roy
Amit Roy
CTCinzia Tesauro
Cinzia Tesauro
AJAnn-Katrine Jakobsen
Ann-Katrine Jakobsen
BKBirgitta Knudsen
Birgitta Knudsen
Acquisition of resistance to topoisomerase I (TOP1)-targeting camptothecin (CPT) derivatives is a major clinical problem. Little is known about the underlying chromosomal and genomic mechanisms. We characterized the CPT-K5 cell line expressing mutant CPT-resistant TOP1 and its parental T-cell derived acute lymphoblastic leukemia CPT-sensitive RPMI-8402 cell line by karyotyping and molecular genetic methods, including subtractive oligo-based array comparative genomic hybridization (soaCGH) analysis. Karyotyping revealed that CPT-K5 cells had acquired additional structural aberrations and a reduced modal chromosomal number compared to RPMI-8402. soaCGH analysis identified vast copy number alterations and >200 unbalanced DNA breakpoints distributed unevenly across the chromosomal complement in CPT-K5. In addition, the short tandem repeat alleles were found to be highly different between CPT-K5 and its parental cell line. We identified copy number alterations affecting genes important for maintaining genome integrity and reducing CPT-induced DNA damage. We show for the first time that short tandem repeats are targets for TOP1 cleavage, that can be differentially stimulated by CPT.